New Breast Cancer Treatment Targets Cancer Cells, Prolongs Survival

From WSJ.com

CHICAGO—An experimental drug being developed by Roche Holding AG delayed progression of disease and appeared to improve survival in women with a specific type of breast cancer in a study that illustrates the potential of an emerging new strategy for treating cancer.

The study involved a drug known as T-DM1, which combines Roche's cancer drug Herceptin with a potent chemotherapy agent in a treatment designed to be delivered directly to the cancer cell. The intent is to hit the tumor with a double punch that is more powerful than Herceptin alone and that limits the side effects associated with chemotherapy.

Read more about T-DM1